Thrombopoietin receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Thrombopoietin receptor shows approved-linked disease relevance led by Thrombocytopenia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P40238. Start with Thrombocytopenia, then reuse UniProt P40238 as the stable protein anchor across project notes and exports.
Start with Thrombocytopenia, then reuse UniProt P40238 as the stable protein anchor across project notes and exports.
Thrombopoietin receptor shows approved-linked disease relevance led by Thrombocytopenia. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.
Start review with Thrombocytopenia because it currently carries approved-linked support. Linked drugs include AVATROMBOPAG, AVATROMBOPAG MALEATE, ELTROMBOPAG CHOLINE, ELTROMBOPAG OLAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyThrombopoietin receptor
Review this target as Thrombopoietin receptor, mapped to UniProt P40238. Sequence length is 635 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Thrombopoietin receptor as ChEMBL target CHEMBL1864, mapped to UniProt P40238. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Thrombopoietin receptor is the right protein anchor across sources, using UniProt P40238 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Thrombocytopenia is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Thrombopoietin receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P40238 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Thrombopoietin receptor |
| UniProt Accession | P40238 |
| Component Type | Protein |
| Sequence Length | 635 aa |
Thrombopoietin receptor
Review this target as Thrombopoietin receptor, mapped to UniProt P40238. Sequence length is 635 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Thrombopoietin receptor shows approved-linked disease relevance led by Thrombocytopenia. 5 more disease programs remain visible in the same review block.
Start review with Thrombocytopenia because it currently carries approved-linked support. Linked drugs include AVATROMBOPAG, AVATROMBOPAG MALEATE, ELTROMBOPAG CHOLINE, ELTROMBOPAG OLAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1257604 | 8.52 | EC50 | 3.0 | Preclinical |
| CHEMBL1257603 | 8.22 | EC50 | 6.0 | Preclinical |
| CHEMBL429295 | 8.15 | EC50 | 7.0 | Preclinical |
| CHEMBL248218 | 8.05 | EC50 | 9.0 | Preclinical |
| CHEMBL455654 | 8.0 | EC50 | 10.0 | Preclinical |
| CHEMBL248390 | 7.96 | EC50 | 11.0 | Preclinical |
| CHEMBL249471 | 7.89 | EC50 | 13.0 | Preclinical |
| CHEMBL3144775 | 7.7 | EC50 | 20.0 | Preclinical |
| CHEMBL498173 | 7.68 | EC50 | 21.0 | Preclinical |
| CHEMBL440231 | 7.66 | EC50 | 22.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 12 | 166 | 6.7 |
| assay format | 3 | 50 | 6.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 7 | 52 | 6.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |